Topics:

Multiple Myeloma

Stringent Complete Response in Multiple Myeloma Associated With Best Survival Outcomes

Patients able to achieve stringent complete response after undergoing autologous stem-cell transplantation for multiple myeloma achieved improved long-term outcomes, including overall survival and time to progression, compared with patients who achieved lesser levels of response.

Multiple Myeloma

The International Myeloma Working Group recently published a series of consensus statements discussing the use of MRI in the treatment of multiple myeloma.

A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.

Cigarette smoking is not a risk factor for multiple myeloma, according to the results of a pooled analysis of nine case-control studies.

The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.

In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.

Adding carfilzomib to lenalidomide and dexamethasone resulted in a higher PFS and better overall quality of life for relapsed multiple myeloma patients.

Early trial data support further evaluation of ixazomib combined with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma.

Pages

Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.